MCLA 128

Drug Profile

MCLA 128

Alternative Names: MCLA-128

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merus
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 13 Mar 2018 Merus has patent protection for Spleen to Screen® technology in USA, Europe, Asia, Australia
  • 13 Mar 2018 Merus has patents pending for Spleen to Screen® technology in USA and other undisclosed countries
  • 26 Jan 2018 Phase-II clinical trials in Breast cancer (Metastatic disease, Late-stage disease, Combination therapy, Chemotherapy-induced, Second-line therapy or greater) in USA, Belgium, France, Portugal, Spain (IV) (NCT03321981)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top